Molecular Pathology FAST Series

SNO's Molecular Pathology Special Interest Track is pleased to announce the quarterly event for the SNO Pathology FAST (First Author Series Talk) webinar series. The webinar entitled Spatial Immunogenomic Heterogeneity of Malignant Brain Tumors will occur live on Monday, May 16, 2022, at 1:00pm - 2:00pm EDT.

Learning Objectives
- Describe the spatial intratumoral heterogeneity of malignant gliomas and brain metastases at the genomic and immunologic level.
- Explore the translational significance of intratumoral heterogeneity on the design of targeted therapies.
- Understand the unique immunogenomic state of hypermutated recurrent gliomas and how it could dictate clinical management.

There is no charge to attend the webinar. For full details and to register click here.

Clinical Trial Design Workshop – Application Deadline this Friday!

The deadline is approaching to apply for the 4th Annual Introduction to Clinical Trial Design and Protocol Development Workshop. This year’s workshop will be held in person on Thursday, August 11, 2022 in Toronto, Canada, prior to the Conference on CNS Clinical Trials and Brain Metastases, Co-Sponsored by SNO and ASCO. New this year is an expanded offering to include an introductory protocol development option for participants without prior experience writing a clinical trial protocol or conducting clinical research. For full details, please click here.

Featured Clinical Trial

Testing the Addition of the Immune Therapy Drugs, Tocilizumab and Atezolizumab, to Radiation Therapy for Recurrent Glioblastoma

NRG-BN010 is a phase II trial that studies the combination of tocilizumab (monoclonal


antibody against IL-6) in combination with atezolizumab (PD-L1 inhibitor) and stereotactic radiation therapy in treating patients with first recurrence of glioblastoma. The study is sponsored by NRG. Read more here.

From The Journals

From Neuro-Oncology
RBBP4-p300 axis modulates expression of genes essential for cell survival and is a potential target for therapy in glioblastoma
RBBP4 activates transcription by histone acetylation, but the partner histone acetyltransferases are unknown. Thus, we investigated the hypothesis that RBBP4 interacts with p300 in a complex in glioblastoma (GBM). Click to read the full article.

SNO Career Center

This Week’s Featured Listing
The Department of Medical Oncology & Therapeutics Research at City of Hope National Medical Center is seeking a medical oncologist who has experience treating or is interested in being mentored to specialize in treating patients with sarcoma, melanoma and/or brain tumors. Click here to apply or see other postings!

Upcoming SNO and SNO Affiliated Events

2022 SNO Annual Meeting and Education Day - Call for Abstracts
Abstract deadline - June 1, 2022
For information on the submission categories and requirements, please click here.
To submit an abstract, please click here.

The 20th International Symposium of Pediatric Neuro-Oncology (ISPNO 2022)
June 12-15, 2022, in Hamburg
Register Here
For information about travel grants for LMIC countries, please click here.

2022 SNO Introduction to Clinical Trial Design and Protocol Development Workshop
August 11, 2022
Deadline Extended! - April 22, 2022
Apply Here

2nd Annual Conference on Clinical Trials and Brain Metastases
August 12-13, 2022
Registration and Accommodations Coming Soon.
SNO Membership

It’s Time to Spring Clean Your SNO Account!
Make sure you do not miss any important updates or journal deliveries from SNO by spring cleaning your SNO account today. Ensure your contact information is up-to-date and your membership is current by clicking here to log into your SNO account. Need assistance? Please contact Caroline Noor at caroline@soc-neuro-onc.org or 830.321.0615.

SNO Digest is written and distributed by the Society for Neuro-Oncology. All content, including images, may not be reproduced unless permission is granted from SNO. If you would like to contribute to upcoming issues of the SNO Digest or if you have questions, please contact us at snodigest@soc-neuro-onc.org.